Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Ryan C. Lynch, Abraham Avigdor, Matthew S McKinney, Shankara Paneesha, Björn Wahlin, John S Hrom, David Cunningham, Nicholas Morley, Miguel Canales, Mariana Bastos-Oreiro, David Belada, Liliana Devizzi, Fred Zheng, Douglas J DeMarini, Wei Jiang, Marek Trněný

Blood (2021) 138 (Supplement 1): 813.

https://doi.org/10.1182/blood-2021-147918

Published: 2021

Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Ryan C. Lynch, MD, Shankara Paneesha, MD, Abraham Avigdor, MD, Matthew S McKinney, Björn E Wahlin, MD PhD, John S Hrom, David Belada, MD PhD, Miguel Canales, David Cunningham, MD FRCP, FMedSci, Liliana Devizzi, Nicholas Morley, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Marek Trněný, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134869

Published: 2020

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Jordan Gales, MD, Matthew S. McKinney, MD, Harry P. Erba, MD PhD, Chad M. McCall, MD PhD

Blood (2019) 134 (Supplement_1): 5131.

https://doi.org/10.1182/blood-2019-125135

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Xiang Li, Rachel Kositsky, Anupama Reddy, PhD, Cassandra Love, Kikkeri Naresh, Jean L. Koff, MD, Ilja Nystrand, Sirpa Leppä, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Johannes Dunkel, Panu Kovanen, MD PhD, Qiu Qin, Govind Bhagat, MD, Rebecca J Leeman-Neill, MDPhD, Rashmi S. Goswami, MD PhD, Sarah Wildeman, Jan Delabie, MDPhD, Richard Burack, MD PhD, Andrew G Evans, MD PhD, Catalina Amador, MD, Ji Yuan, Hina Naushad Qureishi, Shaoying Li, MD, Jie Xu, C. Cameron Yin, MD PhD, Anne Ortved Gang, Peter H. Norgaard, MDPhD, Mette Ø Pedersen, MD, Jason Yongsheng Chan, MBBS, MRCP, Daryl Ming Zhe Cheah, Shin Yeu Ong, MD FRCPath, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Lianne Lee, Felik Paulua, Sarah L. Ondrejka, DO, Eric D. Hsi, MD, Magdalena Czader, MD PhD, Lin Wang, PhD, Amber Landis, Michael C. Churnetski, David L. Jaye, MD, Christopher R. Flowers, MD MS, Chad M. McCall, MD PhD, Jadee Neff, MD PhD, Matthew S. McKinney, MD, Yuri Fedoriw, Eric Powers, Nathan D Montgomery, MD, Agata M. Bogusz, MDPhD, Andrea Stafford Hintz, HSLT, Alexandra E. Kovach, MD, Nishitha Reddy, MD, Mary Ann Thompson Arildsen, MD PhD, Emily F Mason, MD PhD, Ridas Juskevicius, MD, William Choi, MBBS,MRCP, Rex Au-Yeung, Eric Tse, MBBS, PhD FRCP, FRCPath, Vincent Sarno, Amy Chadburn, MD, Rafael Lopez, MD, Jennifer R Chapman, MD, Amir Behdad, MD, Neta Goldschmidt, MD, John Goodlad, MD, Cathy Burton, Raju Pillai, MD, Abner Louissaint, Jr., MD PhD, Dina Sameh Soliman, MD MB, MMSc, Razvan Panea, Tushar Dave, Barbara Xiong, Eileen Smith, Sandeep Dave, MD

Blood (2019) 134 (Supplement_1): 19.

https://doi.org/10.1182/blood-2019-130255

Published: 2019

Journal Articles

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

Nicholas Davis, PhD, Matthew S. McKinney, MD, Anupama Reddy, PhD, Cassandra Love, Eileen Smith, Lanie Happ, Sandeep Dave, MD

Blood (2018) 132 (Supplement 1): 1370.

https://doi.org/10.1182/blood-2018-99-119639

Published: 2018

Journal Articles

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Luke Paul Akard, MD, Samantha Jaglowski, MD, Steven M. Devine, MD, Matthew S. McKinney, MD, Michael Vasconcelles, MD, Heather Huet, PhD, Seth Ettenberg, PhD, Ann Ranger, PhD, Jeremy S. Abramson, MD MMSc

Blood (2017)

https://doi.org/10.1182/blood.V130.Suppl_1.580.580

Published: 2017

Journal Articles

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

Anthony D. Sung, MD, Carlos M. de Castro, MD, Thomas W. LeBlanc, MD MA, Gwynn D. Long, MD, Donna B. Adams, NP, Danielle M. Brander, MD, Sandeep Dave, MD, Louis F. Diehl, MD, Phuong Linh Doan, MD, Therese Hennig, PA, Yubin Kang, MD, Matthew S. McKinney, MD, Lindsay A.M Rein, MD, Dorothy A. Sipkins, MD, Yiping Yang, MD PhD, Nelson J. Chao, MDM.B.A, David A. Rizzieri, MD

Blood (2017) 130 (Supplement 1): 3853.

https://doi.org/10.1182/blood.V130.Suppl_1.3853.3853

Published: 2017

Journal Articles

SETD2 Functional Loss through Mutation or Genetic Deletion Promotes Expansion of Normal and Malignant γδ T Cells through Loss of Tumor Suppressor Function and Upregulation of Oncogenic Pathways

Matthew S. McKinney, MD, Andrea B. Moffitt, Rachel E Rempel, PhD, Deepthi Rajagopalan, Jane Healy, MD PhD, Tiffany Tzeng, Jyotishka Datta, Cassandra Love, David Dunson, Yuan Zhuang, PhD, Sandeep Dave, MD

Blood (2016) 128 (22): 1052.

https://doi.org/10.1182/blood.V128.22.1052.1052

Published: 2016

Journal Articles

Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas

Matthew S. McKinney, MD, Anne W Beaven, MD, Andrea Moffitt, Jason Landon Smith, MD, Eric Lock, PhD, Dereje Jima, Jane Healy, MD PhD, Guojie Li, Adrienne Greenough, PhD, Cassandra L Love, MS, Xiao Yi Yang, MD, David Dunson, PhD, Herbert Kim Lyerly, MD, Leon Bernal-Mizrachi, MD, Randy D. Gascoyne, MD, Sandeep S. Dave, MD

Blood (2014) 124 (21): 271.

https://doi.org/10.1182/blood.V124.21.271.271

Published: 2014

Journal Articles

ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom

Blood (2012) 120 (21): 898.

https://doi.org/10.1182/blood.V120.21.898.898

Published: 2012

Journal Articles

Alterations in Metabolism and Mitochondrial Respiration Are Associated with Response to Targeted Inhibition of WNT Signaling in Lymphomas

Matthew S. McKinney, MD, Cassandra L Love, MS, Jenny Zhang, Sandeep S. Dave, MD, MS

Blood (2012) 120 (21): 778.

https://doi.org/10.1182/blood.V120.21.778.778

Published: 2012

NARROW

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Clinical Outcomes of Microtransplantation for Older Adults with Acute Myeloid Leukemia

SETD2 Functional Loss through Mutation or Genetic Deletion Promotes Expansion of Normal and Malignant γδ T Cells through Loss of Tumor Suppressor Function and Upregulation of Oncogenic Pathways

Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas

ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom

Alterations in Metabolism and Mitochondrial Respiration Are Associated with Response to Targeted Inhibition of WNT Signaling in Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only